Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-02-19, 04:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-02-03, 19:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-24, 10:14
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-21, 20:33
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-12-20, 20:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-12-19, 20:53
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-12-16, 15:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-12-02, 02:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-11-14, 09:14
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-10-30, 13:00
